Considering the consistent DFS, safety, and cost-effectiveness benefits of first-generation EGFR-TKI application for early-stage EGFR mutation-positive NSCLC patients, it is suggested that the reimbursement policy could be further expanded. This evidence concerns the gene EGFR and non-small cell lung carcinoma.